Dual-specificity Phosphatase 9 Protects Against Non-alcoholic Fatty Liver Disease in Mice via ASK1 Suppression.

@article{Ye2018DualspecificityP9,
  title={Dual-specificity Phosphatase 9 Protects Against Non-alcoholic Fatty Liver Disease in Mice via ASK1 Suppression.},
  author={Ping Ye and Mei Xiang and H. Y. M. Liao and Jijun Liu and Hongbo Robert Luo and Yayun Wang and Ling Huang and Manhua Chen and Jiahong Xia},
  journal={Hepatology},
  year={2018}
}
Non-alcoholic fatty liver disease (NAFLD), ranging from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), is the leading cause of chronic liver diseases. Until now, no medications for NAFLD have been approved by relevant governmental agencies. Dual-specificity phosphatase 9 (Dusp9) is a member of the DUSP protein family. Dusp9 is expressed in insulin-sensitive tissues, and its expression may be modified with the development of insulin resistance (IR). However, the… CONTINUE READING
BETA

Citations

Publications citing this paper.

University of Dundee Dual-specificity MAP kinase phosphatases in health and disease

Ole-Morten Seternesa, Andrew M. Kidgerb, Stephen M. Keysec
  • 2018

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

NAFLD, NASH and liver cancer

  • Nature Reviews Gastroenterology &Hepatology
  • 2013
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2008
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…